OS Therapies

OSTX · NYSE American

$1.26−$0.01 (−0.79%)TodayMarket closed · Oct 20, 8:00 PM ET

Prev close $1.27

About OSTX

OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2024-08-01. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.

Employees: 4
Headquarters: Rockville, Maryland
Listed: Aug 1, 2024
Sector: Health Care
Industry: Biotechnology
Website: ostherapies.com

Leadership

OS Therapies executives
Name	Title	Since	Age
Paul Romness	—	2018	59
Christopher Acevedo	—	—	62
Robert Petit	—	—	66
Gerald Commissiong	—	—	43
Karim Galzahr	—	—	52
John Ciccio	—	—	45
Olivier Jarry	—	—	64
Avril Mckean Dieser	—	—	52
Theodore Search	—	—	44

Similar companies

Companies in the same industry as OS Therapies

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.